Overall survival with crizotinib and next-generation ALK inhibitors in ALK-positive non-small-cell lung cancer (IFCT-1302 CLINALK): a French nationwide cohort retrospective study

por Duruisseaux, Michaël, Besse, Benjamin, Cadranel, Jacques, Pérol, Maurice, Mennecier, Bertrand, Bigay-Game, Laurence, Descourt, Renaud, Dansin, Eric, Audigier-Valette, Clarisse, Moreau, Lionel, Hureaux, José, Veillon, Remi, Otto, Josiane, Madroszyk-Flandin, Anne, Cortot, Alexis, Guichard, François, Boudou-Rouquette, Pascaline, Langlais, Alexandra, Missy, Pascale, Morin, Franck, Moro-Sibilot, Denis
Publicado 2017